PT2928898T - Inibidores de beta-lactamase - Google Patents

Inibidores de beta-lactamase

Info

Publication number
PT2928898T
PT2928898T PT138611983T PT13861198T PT2928898T PT 2928898 T PT2928898 T PT 2928898T PT 138611983 T PT138611983 T PT 138611983T PT 13861198 T PT13861198 T PT 13861198T PT 2928898 T PT2928898 T PT 2928898T
Authority
PT
Portugal
Prior art keywords
beta
lactamase inhibitors
lactamase
inhibitors
Prior art date
Application number
PT138611983T
Other languages
English (en)
Original Assignee
Venatorx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venatorx Pharmaceuticals Inc filed Critical Venatorx Pharmaceuticals Inc
Publication of PT2928898T publication Critical patent/PT2928898T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PT138611983T 2012-12-07 2013-12-05 Inibidores de beta-lactamase PT2928898T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261734900P 2012-12-07 2012-12-07
US201361783238P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
PT2928898T true PT2928898T (pt) 2021-07-05

Family

ID=50884012

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138611983T PT2928898T (pt) 2012-12-07 2013-12-05 Inibidores de beta-lactamase

Country Status (17)

Country Link
US (5) US9422314B2 (pt)
EP (2) EP2928898B1 (pt)
JP (2) JP6403219B2 (pt)
KR (1) KR102147420B1 (pt)
CN (1) CN105026407B (pt)
AU (1) AU2013355110B2 (pt)
BR (1) BR112015013123B1 (pt)
CA (1) CA2893943C (pt)
ES (1) ES2878118T3 (pt)
HK (1) HK1217334A1 (pt)
HR (1) HRP20210879T1 (pt)
IL (1) IL239212B (pt)
PL (1) PL2928898T3 (pt)
PT (1) PT2928898T (pt)
RU (1) RU2654692C2 (pt)
WO (1) WO2014089365A1 (pt)
ZA (1) ZA201504200B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6266978B2 (ja) 2010-08-10 2018-01-24 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP2928898B1 (en) * 2012-12-07 2021-04-14 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) * 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201591004A1 (ru) 2013-01-04 2016-02-29 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2016015093A (es) * 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
EP3882252A1 (en) 2014-06-11 2021-09-22 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
EA201692301A1 (ru) * 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10364257B2 (en) 2014-12-19 2019-07-30 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
KR20170115042A (ko) * 2014-12-23 2017-10-16 베르겐바이오 에이에스에이 Akt 키나아제의 저해제
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) * 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) * 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
BR112018077015B1 (pt) * 2016-06-30 2022-05-03 Qpex Biopharma, Inc Derivados de ácido borônico e usos terapêuticos dos mesmos
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) * 2016-08-15 2016-09-28 Univ Oslo Compounds
JP2020510661A (ja) * 2017-03-06 2020-04-09 ベナトルクス ファーマシューティカルズ，インク． β−ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用
WO2018199291A1 (ja) * 2017-04-28 2018-11-01 大日本住友製薬株式会社 ヘテロ環誘導体
GB201708002D0 (en) 2017-05-18 2017-07-05 Univ Oxford Innovation Ltd ß-Lactamase inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
JOP20200101A1 (ar) * 2017-11-01 2022-10-30 Melinta Therapeutics Inc تخليق مشتقات إستر بورونات واستخداماتها
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2019259818B2 (en) 2018-04-27 2023-06-01 Sumitomo Pharma Co., Ltd. Oxo-substituted compound
US20210198288A1 (en) 2018-05-25 2021-07-01 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US20220054513A1 (en) 2018-09-12 2022-02-24 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
AU2020256179A1 (en) * 2019-04-02 2021-11-18 VenatoRx Pharmaceuticals, Inc. Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof
MX2022004912A (es) 2019-10-25 2022-08-25 Sumitomo Pharma Co Ltd Novedoso compuesto de anillo condensado sustituido.
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
EP4201942A1 (en) 2020-08-20 2023-06-28 Phaeno Therapeutics Co., Ltd. Boracic acid compound
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2022187362A1 (en) * 2021-03-02 2022-09-09 Case Western Reserve University Β-lactamase inhibitors and uses thereof
MX2023012004A (es) 2021-04-13 2023-10-20 Tuojie Biotech Shanghai Co Ltd DERIVADO DEL ÁCIDO BÓRICO QUE ACTÚA COMO INHIBIDOR DE LA ß-LACTAMASA.
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE41109B1 (en) 1974-04-20 1979-10-24 Beecham Group Ltd Novel -lactam antibiotic from streptomyces clavuligerus
IT1283467B1 (it) * 1996-07-19 1998-04-21 Menarini Farma Ind Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni
PL354249A1 (en) 1999-09-17 2003-12-29 Abbott Gmbhabbott Gmbh Pyrazolopyrimidines as therapeutic agents
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
JP2007505950A (ja) 2003-06-10 2007-03-15 フルクラム・ファーマシューティカルズ・インコーポレーテッド β−ラクタマーゼ阻害剤およびその使用方法
BRPI0509587A (pt) 2004-03-30 2007-09-25 Millennium Pharm Inc processo em grande escala para preparar um composto de éster borÈnico, aminoborÈnico e composição que compreende um solvente de éter
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
CA2629570C (en) 2005-12-07 2012-11-27 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
WO2009064414A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
MY162532A (en) 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
AR076667A1 (es) * 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
JP6266978B2 (ja) * 2010-08-10 2018-01-24 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
EP2768503A1 (en) 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
CA2847336C (en) 2011-09-04 2021-09-07 Glytech, Inc. Glycosylated polypeptide and drug composition containing said polypeptide
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
SG11201403254QA (en) 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
KR101782235B1 (ko) 2012-12-03 2017-09-26 에프. 호프만-라 로슈 아게 치환된 트라이아졸 붕소산 화합물
EP2928898B1 (en) 2012-12-07 2021-04-14 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201591004A1 (ru) 2013-01-04 2016-02-29 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
EP2943204B1 (en) * 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
US20150361107A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
EP3882252A1 (en) 2014-06-11 2021-09-22 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR101935186B1 (ko) 2014-09-04 2019-01-03 시오노기세야쿠 가부시키가이샤 카테콜기를 갖는 세팔로스포린류를 함유하는 제제
US10364257B2 (en) 2014-12-19 2019-07-30 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
JP2020510661A (ja) 2017-03-06 2020-04-09 ベナトルクス ファーマシューティカルズ，インク． β−ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
WO2019118358A1 (en) 2017-12-11 2019-06-20 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
US20210198288A1 (en) 2018-05-25 2021-07-01 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors

Also Published As

Publication number Publication date
PL2928898T3 (pl) 2021-10-25
US20190225628A1 (en) 2019-07-25
US20140171390A1 (en) 2014-06-19
ZA201504200B (en) 2017-09-27
ES2878118T3 (es) 2021-11-18
CN105026407A (zh) 2015-11-04
US9828391B2 (en) 2017-11-28
IL239212B (en) 2019-10-31
JP2018184409A (ja) 2018-11-22
EP2928898B1 (en) 2021-04-14
IL239212A0 (en) 2015-07-30
RU2654692C2 (ru) 2018-05-22
EP3922635A1 (en) 2021-12-15
WO2014089365A1 (en) 2014-06-12
CA2893943C (en) 2021-03-02
EP2928898A1 (en) 2015-10-14
US20160326189A1 (en) 2016-11-10
CA2893943A1 (en) 2014-06-12
US9422314B2 (en) 2016-08-23
US20150291630A1 (en) 2015-10-15
HRP20210879T1 (hr) 2021-08-20
EP2928898A4 (en) 2016-06-29
KR20150109348A (ko) 2015-10-01
RU2015126912A (ru) 2017-01-12
US8912169B2 (en) 2014-12-16
CN105026407B (zh) 2017-09-08
KR102147420B1 (ko) 2020-08-25
HK1217334A1 (zh) 2017-01-06
JP6403219B2 (ja) 2018-10-10
BR112015013123B1 (pt) 2021-02-17
AU2013355110B2 (en) 2017-11-09
BR112015013123A2 (pt) 2017-07-11
JP2016502973A (ja) 2016-02-01
AU2013355110A1 (en) 2015-07-02
US20180194783A1 (en) 2018-07-12
US10214547B2 (en) 2019-02-26
US10669290B2 (en) 2020-06-02

Similar Documents

Publication Publication Date Title
ZA201504200B (en) Beta-lactamase inhibitors
HRP20180450T1 (hr) Heterobiciklični spojevi kao inhibitori beta-laktamaze
EP2970340A4 (en) BETA-Lactamase INHIBITORS
EP2943204A4 (en) BETA-Lactamase INHIBITORS
HK1211921A1 (en) Inhibitor compounds
EP2831069A4 (en) ISOXAZOL-beta-lactamase INHIBITORS
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
HK1211927A1 (en) Aggrecanase inhibitors
HK1209422A1 (en) Fbxo3 inhibitors fbxo3
HK1209105A1 (en) Vegfr3 inhibitors vegfr3
HK1209104A1 (en) Vegfr3 inhibitors vegfr3
EP2922535A4 (en) thrombin inhibitors
IL238391A (en) Rock inhibitors
EP2882430A4 (en) ANTIBACTERIAL INHIBITORS
GB201211019D0 (en) Inhibitor compounds
EP2830624A4 (en) thrombin inhibitors
GB201223308D0 (en) Enzyme inhibitors
GB201210390D0 (en) Antibacterial enzyme inhibitors
GB201200094D0 (en) Antibacterial enzyme inhibitors
GB201120474D0 (en) Inhibitors